Pozen Inc said drug Treximet failed to get the pediatric exclusivity, the regulatory exclusivity is set to expire on April 15.Pozen Inc has acquired three patents on Treximet.Out of which two of the patents expire in August 2017 and one expires in October 2025.These patents have been challenged by four major pharma's namely: Par Pharmaceuticals Inc,Alphapharm Pty Ltd, Teva, and Dr. Reddy's Laboratories Inc. Meanwhile during the current battle, Pozen's market dominance seems to drop as its shares observed 7 percent fall, this wednesday on Nasdaq.
(Image by D. Sharon Pruitt )
